Immunotherapy drug shows promise in keeping early lung cancer at bay
NCT ID NCT02504372
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 33 times
Summary
This study tested whether the immunotherapy drug pembrolizumab (Keytruda) could help prevent lung cancer from coming back in people with early-stage non-small cell lung cancer (stages IB to IIIA) who had already had surgery and standard chemotherapy. About 1,177 participants received either pembrolizumab or a placebo every three weeks for up to a year. The main goal was to see if the drug extended the time before the cancer returned or the patient died.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.